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Background: The bronchial mucosa is protected by a specialized immune system focused on 
the prevention of colonization and infection by potentially pathogenic microorganisms (PPMs). 
Immunoglobulin A (IgA) is the principal antibody involved in this mechanism. A defective 
immune barrier may facilitate the recurrent presence of PPMs in COPD.
Purpose: The aim of this study was to determine IgA-mediated bronchial specific immune 
responses against Pseudomonas aeruginosa in stable patients with severe disease.
Methods: COPD patients with good-quality sputum samples obtained during stability were 
included and classified according to the presence or absence of chronic bronchial coloniza-
tion by P. aeruginosa. Levels of specific IgA for P. aeruginosa in sputum were determined 
by ELISA and expressed as ratios, using the pooled level of 10 healthy subjects as reference 
(optical density
450
 patient/control).
Results: Thirty-six stable COPD patients were included, 15 of whom had chronic colonization 
by P. aeruginosa. Levels of specific IgA against P. aeruginosa in stable non-colonized patients 
were lower than those in healthy subjects (IgA ratio: median =0.15 [interquartile range {IQR} 
0.05–0.36]). Colonized patients had higher levels, (1.56 [IQR 0.59–2.79]) (p,0.001, Mann–
Whitney U test), with figures equivalent but not exceeding the reference value.
Conclusion: IgA-based immune response against P. aeruginosa was low in severe COPD 
patients. Levels of specific IgA against this microorganism were higher in colonized patients, 
but did not attain clear-cut levels above the reference. An impaired local response against 
P. aeruginosa may favor chronic colonization and recurrent infections in severe COPD.
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Introduction
The bronchial epithelium represents a first line of the respiratory mucosal host defense 
through the local production of antimicrobial peptides and proteins, the transport and 
secretion of immunoglobulins to the epithelial surface, and mucociliary clearance.1,2 
Secretory immunoglobulin A (SIgA) is the main immunoglobulin in the bronchial 
mucosa.3 It is produced as dimeric IgA, which is able to bind to the polymeric immu-
noglobulin receptor (pIgR) in the epithelium, allowing the transcytosis of IgA across 
the epithelial cell.4 Once in the epithelial surface, proteolytic cleavage releases the 
dimeric IgA bound to the extracellular domain of the receptor to form SIgA.5
SIgA agglutinates airborne antigens and microorganisms through a process 
known as immune exclusion, preventing them from activating or directly injuring 
airway epithelial cells.6 In normal conditions, inhaled particles and microorganisms 
are trapped in the surface mucus, agglutinated by specific SIgA, and then removed 
via the mucociliary escalator.2 In chronic obstructive pulmonary disease (COPD), the 
airway epithelium is structurally and functionally abnormal and unable to maintain 
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the normal dynamics of the mucosal barrier.2 In addition 
to an impairment in mucociliary clearance mechanisms, a 
decreased expression of pIgR also characterizes the bronchial 
epithelium in COPD, resulting in a deficiency of SIgA on 
the mucosal surfaces.7,8
Lower levels of SIgA in the bronchial tree may contribute 
to the impaired mucosal defense against pathogens that is 
characteristic of COPD, favoring bacterial colonization and 
recurrent bronchial infections by potentially pathogenic 
microorganisms (PPMs), which are common events in the 
natural history of COPD.
Bronchial colonization by PPMs such as Haemophilus 
influenzae has been previously related to lower levels of 
specific IgA in moderate COPD.9 The objective of the pres-
ent study was to determine the levels of specific IgA against 
Pseudomonas aeruginosa in sputum samples from severe 
COPD patients in their stable periods, either non-colonized 
or colonized by this PPM, in order to assess the relationships 
between the bronchial immunoglobulin defense barrier and 
chronic colonization by P. aeruginosa in these patients.
Methods
ethics approval and consent to 
participate
The study was reviewed and approved by the Comité Etic 
d’Investigació Clínica de l’Hospital Universitari de Bellvitge 
(HUB). Sputum samples and bacterial strains were recorded 
in an anonymized database. Written informed consents were 
collected from patients and controls according to the HUB 
ethics committee requirements.
Design, patients, and definitions
A cross-sectional analysis of the bronchial IgA-mediated 
immune response against P. aeruginosa in severe COPD 
patients was performed. Participants were selected from 
a previously described hospital-based prospective cohort 
regularly attending an outpatient respiratory clinic for sched-
uled and exacerbation visits.10 Patients with good-quality 
sputum samples during stability were included and classified 
according to the presence of chronic bronchial colonization 
by P. aeruginosa, which was diagnosed when this PPM was 
recovered from the sputum sample studied and in two or more 
additional samples in the interval of a year.
Clinical and functional variables
Demographic and clinical data were recorded at baseline. 
Patients answered an epidemiologic questionnaire that 
covered smoking habits, respiratory symptoms, and previous 
exacerbations. Functional characterization included forced 
spirometry and reversibility testing.11 Forced vital capacity 
and forced expiratory volume in 1 second (FEV
1
) were mea-
sured with the same dry rolling seal spirometer (Sibelmed, 
Sibelgroup, Barcelona, Spain) and expressed as absolute 
values (mL) and percentages of the reference values obtained 
from age- and height-adjusted selected volunteers from the 
Barcelona area.12 COPD was diagnosed in accordance with 
the criteria of the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD).15
Sputum collection and microbiology 
processing
Spontaneous sputum samples were collected from each 
patient in stability. Only good-quality sputum samples were 
considered for the study.13 Quantitative cultures and PCR 
detection of atypical bacteria were performed, as previously 
described.10 For the measurement of specific immunity 
against P. aeruginosa, the sputum supernatant was separated 
after dilution of the sputum with 1/10 dilution of dithiothre-
itol (Sputasol, Oxoid; Thermo Fisher Scientific, Waltham, 
MA, USA) and neutralization with phosphate-buffered 
saline (PBS).
Specific immunity against P. aeruginosa in 
sputum
ELISA was used to determine the IgA antibody level against 
P. aeruginosa in the supernatant of the sputum samples 
recovered. The capture antigen was prepared as follows: 10 
clinical isolates (5 mucoid and 5 non-mucoid) were grown 
overnight on Tryptone Soy Agar (TSA) plates (Oxoid) at 
37°C and 5% CO
2
. These P. aeruginosa strains were colo-
nizing strains isolated from respiratory patients attending 
a chest outpatient clinic. Several colonies were inoculated 
to brain heart infusion (BHI) broth (Oxoid) and grown 
until logarithmic (log) phase. Bacterial concentration was 
adjusted to optical density (OD) 0.5–0.6 at a wavelength of 
600 nm (~1×106 cfu/mL), and the ten isolates were mixed 
to obtain a suspension of 1×106 cfu/mL. Fifty microliters of 
this P. aeruginosa suspension was used to coat each well on 
a microtiter plate (Corning, NY, USA) and were incubated 
overnight at 37°C.
Between each of the following steps, the wells were 
washed four times with PBS (400 µL/well). After wash-
ing, the wells were blocked by the addition of 200 µL of 
PBS-1% bovine serum albumin (BSA) (Sigma-Aldrich Co., 
St Louis, MO, USA) and incubated at 37°C for 2 hours. 
The wells were then washed, and sputum supernatants 
diluted in PBS were added and incubated for 1 hour at 
37°C. After washing, horseradish peroxidase-conjugated 
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mouse-anti human IgA antibody (Abcam, Cambridge, UK) 
diluted 1:1000 in PBS-1% BSA was added and incubated 
for 1 hour at 37°C. Following another washing, 50 µL of 
3,3′,5,5′-tetramethylbenzidine substrate (Sigma-Aldrich Co.) 
was added to the wells, and after 30 minutes, the reaction 
was stopped with 50 µL of H
2
SO
4
 1M and the OD was read 
at 450 nm. All samples were run in triplicate, and the final 
result was the average of the scores.
Specific IgA determinations were performed in the 
supernatant of sputum of all patients studied and in a sputum 
supernatant pool of 10 healthy controls from the general 
population who were used as the reference. Results were 
expressed as the OD ratio between patients and the healthy 
control reference (OD patients/OD pool of healthy controls).
statistical analysis
Data were analyzed using the SPSS statistical software 
package version 19 (IBM Corporation, Armonk, NY, USA). 
Results for categorical variables are expressed as absolute and 
relative frequencies and results for continuous variables as 
means and standard deviations (SD) or as medians and inter-
quartile ranges (IQR) when the distribution was not normal.
Patients included in the study were categorized as non-
colonized and chronically colonized by P. aeruginosa. 
The OD of specific IgA against P. aeruginosa (PA-IgA) in 
patients in non-colonized and colonized patients, expressed 
as a ratio of the OD in healthy subjects, was calculated and 
used for the comparison of non-colonized and colonized 
severe COPD.
All analyses were performed using chi-square, Fisher 
exact, or Mann–Whitney U tests as required. Statistical 
tests were two-sided, and a p-value #0.05 was reported as 
statistically significant.
Results
Patient characteristics
The original cohort consisted of 111 severe COPD patients 
who were followed for a minimum of 1 year after enrolment 
and reported one or more exacerbations during this period.10 
Good-quality sputum samples obtained from a stability 
period were available from 36 participants in the cohort, who 
were the target for this study. This population sample had 
a mean age of 70.5 (SD 7) years and severe COPD (mean 
FEV
1
 36 [SD 13] % of the predicted value, range 25–45.0) 
(Table 1). Sputum cultures obtained during stability were 
negative for P. aeruginosa in 21 patients and positive for 
this PPM in the other 15.
Specific IgA against P. aeruginosa in 
sputum
The levels of PA-IgA in non-colonized patients, expressed 
as a ratio of the value in healthy controls, were below 1 
(median =0.15 [0.05–0.36]) (Figure 1) and confirm the low 
level of specific IgA against this microorganism in severe 
COPD patients. Specific PA-IgA levels were significantly 
higher in colonized than in non-colonized patients (1.56 [IQR 
0.59–2.78] vs 0.15 [0.05–0.36], p,0.001, Mann–Whitney 
U test) and attained the levels found in healthy subjects, 
without reaching higher figures.
Table 1 Patient characteristics
Characteristics Total Non-colonized PA-colonized p-value
Patients, n 36 21 15
Age (years), mean (SD) 70 (7.5) 69.6 (7.3) 71.6 (7.8) ns
Male, n (%) 35 (97) 19 (95) 15 (100) ns
Smoking, n (%)
Current smokers
Former smokers
7 (20)
29 (80)
3 (15)
18 (85)
4 (29)
11 (71)
ns
ns
Postbronchodilator FeV1%, mean (sD) 36 (13) 35 (12) 37 (15) ns
exacerbations last year, median (IQr) 0 (0–1) 0 (0–0) 1 (1–3) ,0.001
Abbreviations: FeV1, forced expiratory volume in 1 second; IQR, interquartile range; NS, not significant; PA, Pseudomonas aeruginosa; sD, standard deviation.
Figure 1 Levels of specific IgA against Pseudomonas aeruginosa (optical density 
patients/pool of healthy controls) in severe COPD patients non-colonized and 
colonized by this microorganism.
Note: *Outlier observations.
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Discussion
In this study, specific PA-IgA levels in severe COPD were 
below the reference values and increased to the levels found 
in healthy subjects only when P. aeruginosa was recov-
ered from bronchial secretions. Bronchial colonization by 
P. aeruginosa was not able to stimulate a higher specific 
response in these patients. These results suggest that the 
production of specific IgA against P. aeruginosa is similarly 
impaired in non-colonized and colonized COPD patients 
with advanced disease, given that they do not attain levels 
higher than the non-colonized healthy population when they 
chronically harbor P. aeruginosa in the bronchial tree.
The blunted IgA response of the bronchial mucosa in 
severe COPD patients shown in our study may favor chronic 
colonization and recurrent infections. Dimeric IgA is pro-
duced in subepithelial plasma cells, bound to pIgR, and 
transported to the apical surface of epithelial cells, where it is 
cleaved to form SIgA. Several studies have found a decreased 
expression of pIgR in COPD, which leads to a SIgA deficiency 
in the airway mucosa5,7,8 which is only partially compensated 
by the direct secretion of SIgA by submucosal glands.2 
Furthermore, the SIgA in the bronchial lumen is often trapped 
within mucus plugs in COPD, which disrupt its normal 
distribution along the mucosal surface and prevent it from 
reaching its expected protective functionality.2 The low levels 
of specific IgA against P. aeruginosa found in our study 
confirm the defective production and/or transport of specific 
IgA against common respiratory pathogens in patients with 
severe COPD, whose levels of specific IgA only approach 
those of healthy subjects when colonized by this PPM, and 
even then are unable to surpass these levels.
Severe COPD patients colonized by P. aeruginosa in our 
study showed higher levels of specific PA-IgA than non-
colonized patients. Nonetheless, in spite of the bronchial 
colonization, they did not attain figures above healthy con-
trols. Therefore, our results confirm that the presence of 
P. aeruginosa in the bronchial tree is able to increase the 
production of specific PA-IgA in severe COPD patients, but 
only to levels equivalent to those in non-colonized healthy 
subjects, probably not enough to efficiently remove the PPM 
from the airways in chronically colonized patients. A previ-
ous study focusing on specific IgA against H. influenzae 
(HI-IgA) in moderate COPD patients obtained different 
results, with higher levels of this immunoglobulin in bron-
chial secretions of non-colonized COPD patients than in 
healthy controls.9 Another recent study14 also found higher 
levels of HI-IgA in COPD patients with early disease than 
in healthy controls. These differences in the specific IgA 
response may point to a specific blunted response against 
P. aeruginosa in COPD which favors chronic colonization by 
this microorganism but may also suggest that abnormal IgA 
responses are restricted to severe disease, since the studies 
that reported high IgA levels against H. influenzae had not 
included patients with advanced disease. In mild and moder-
ate COPD, SIgA secreted by both epithelial cells and sub-
mucosal glands maintains the level of total luminal SIgA; in 
severe COPD, however, in which there is a profound surface 
SIgA deficiency, the total luminal content of SIgA decreases, 
as has been shown in bronchoalveolar lavage samples.2
The present study has some limitations that should be 
taken into account. The main limitation is the small sample 
size. We obtained good-quality sputum samples from only 
36 COPD patients, and 15 of them were colonized by 
P. aeruginosa. The other limitation is that we only included 
severe or very severe COPD patients so we were not able 
to analyze the relationship between FEV
1
 and IgA levels. 
Therefore, future studies with larger COPD cohorts including 
patients with moderate disease are needed to confirm our 
results and its validity in patients with early stage COPD.
Conclusion
The specific immune response of the bronchial mucosa 
against P. aeruginosa is impaired in severe COPD patients, 
as shown by their abnormally low levels of specific IgA. 
Specific PA-IgA levels increase in colonized patients without 
attaining levels above those of healthy subjects. These find-
ings confirm a blunted response to P. aeruginosa in severe 
COPD, which may favor chronic colonization and recurrent 
infections by this PPMs.
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